11/10/2009-Biopharmaceutical company Dynavax Technologies (NASDAQ:DVAX) announced Tuesday that it exercised its option to buy all of the shares of Symphony Dynamo Inc.

In doing so, Dynavax will receive approximately $20 million in cash and regain all rights related to its hepatitis C and cancer therapy programs.

However, the transaction is still subject to Dynavax stockholder approval, but is expected to close in Q1 of next year.

Upon closing of the deal, Symphony and its co-investors are expected to own approximately 24% of Dynavax' common stock.

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html